Life sciences industry's highest achievers celebrated at prestigious Awards ceremony

AusBiotech

PR98518

 

PERTH, Australia, Oct, 27, 2022 /PRNewswire=KYODO JBN/ --

 

AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards

 

-Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO

-Company of the Year: Telix Pharmaceuticals

-Emerging Company of the Year: Fusetec

 

AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO and Nicola Forrest

AO

 

Biotech's illustrious Industry Excellence Awards were announced today at the

AusBiotech 2022 national conference in Perth – recognising outstanding

contribution and achievement. The AusBiotech and Johnson & Johnson Innovation

Industry Excellence Awards recognise innovative companies and individuals in

Australia's world-class biotechnology, medical technology and healthcare

sectors.

 

Dr Andrew Forrest AO and Nicola Forrest AO were also awarded the AusBiotech

Life Sciences Legacy Award in recognition of their generous and active support

of medical research and Australian life science innovation.

 

AusBiotech's Chief Executive Officer, Lorraine Chiroiu, said: "These

prestigeous Awards act as a celebration of the cutting-edge innovation

excellence happening across the country and the extraordinary progress that

these individuals and companies have contributed to the health of Australians,

and to the growth of the sector."

 

"Congratulations to the recipients, who demonstrate what can be achieved when

innovation, passion, and drive are accompanied by the vision and leadership

needed to bring novel medicines, medical devices and other new technologies to

patients."

 

Announcing the awards, Ms Kathy Connell, Senior Director, External Innovation

Partnering, ANZ, Johnson & Johnson Innovation, said: "Johnson & Johnson

Innovation is proud to sponsor these awards, and to celebrate and recognise

these exceptional recipients for their commitment to lifescience innovation

excellence. The discovery, development and commercialisation of biomedical

research takes a global effort from diverse ecosystem including scientists,

entrepreneurs, philanthropists and industry partners. This years' awardees

represents contributions from across Australia and we commend their work as

they seek to advance healthcare for humanity around the world."

 

Dr Forrest said: "We are passionate about finding ethical and sustainable

solutions to a range of issues that impact people and the planet, and we trust

that our commitment and passion, in both our philanthropy work and the

commercial investments we make, is helping to make the world a better place.

 

"We back Australian research and businesses, as well as partner with people

across the world to share information and accelerate the development of

breakthrough therapies, life-changing products and medical treatments. We are

investing in the future of Australian healthcare innovation in a way that

hasn't been done here before."

 

More on the 2022 winners

 

Industry Leadership Award Professor Steve Wilton AO, Director Centre for

Molecular Medicine and Innovative Therapeutics and Foundation Chair in

Molecular Therapies, Murdoch University and Director Perron Institute for

Neurological and Translational Science Perth, WA; and Professor Sue Fletcher

AO, Principal Research Fellow Centre for Molecular Medicine and Innovative

Therapeutics Murdoch University and Chief Scientific Officer, PYC Therapeutics

Perth, WA.

Professors Steve Wilton and Sue Fletcher's collaboration and pioneering

research has resulted in the development of three FDA-approved "exon-skipping"

medicines that overcome specific genetic mutations that cause Duchenne Muscular

Dystrophy (DMD).

 

Their contribution to Australia's biotech industry spans more than 25 years,

and their work in antisense oligomer-induced exon skipping puts Australia's

medical research into rare diseases and neuromuscular science on the map. All

three medicines (Exondys 51, Vyondys 53 and Amondys 45) were developed at the

Perron Institute for Neurological and Translational Science with The University

of Western Australia and has been commercialised in partnership with US company

Sarepta Therapeutics.

 

Company of the Year: Telix Pharmaceuticals

Melbourne-headquartered biopharmaceutical company Telix Pharmaceuticals Limited

(Telix) is focused on the development and commercialisation of diagnostic and

therapeutic ('theranostic') radiopharmaceuticals. Founded in 2015, Telix has

moved its lead product Illuccix®, a PSMA PET imaging agent for the detection

and staging of prostate cancer, from academic proof-of-concept to a

commercially-proven product in the space of three short years, with FDA and TGA

approval gained during late 2021 (now reimbursed in both markets), and Health

Canada approval in October 2022.

 

Commerically launching Illuccix® in the US in April 2022, Telix has since

generated USD$50 million (AUD$73 million) in sales; in addition to Australia,

it now has commerical operations in the US, Europe and Japan. The first patient

was imaged in Australia in September 2022, and US-distribution has rapidly

expanded with a network of more than 150 radiopharmacies nationwide; the US

total addressable market for PSMA PET imaging for prostate cancer is estimated

at USD$1-1.5 billion annually. Telix's has further theranostics for oncology

and rare diseases progressing through the pipeline, with more than 20 Telix

sponsored and investigator-led clinical trials spanning Phases 1 – 3.

 

Emerging Company of the Year: Fusetec

Established in 2017, Fusetec's medical technology is already revolutionising

medical training globally. Through its advanced additive manufacturing,

Fusetec's realistic, anatomically accurate bone, skin and muscle is used during

surgical training and reducing the need for medical students, residents and

surgeons to practice on real patients or extremely expensive cadavers. These

medical devices are made to order, and can be designed and manufactured to

simulate specific pathology. Currently available are models in orthopaedics,

otolaryngology, neurology and gynecology, with more surgical displines under

development.

 

Fusetec has secured global partnerships and opened a world-first 3D Advanced

Surgical Training Clinic in South Australia, creating 157 direct jobs in the

fields of research, production and administration; it expects to create an

additional 800 indirect jobs in South Australia within the supply chain,

medical tourism and higher education sectors.

 

AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO and Nicola Forrest

AO

Dr Andrew Forrest AO and Nicola Forrest AO have demonstrated a deep commitment

to finding ethical and sustainable solutions to a range of global issues as

diverse as childhood cancer, ending modern slavery, and ocean conservation.

 

Among Australia's most active philanthropists and investors, they have invested

more than $2.6 billion since 2001 through the Minderoo Foundation which they

co-Chair.

 

Their commitment to improving equitable health outcomes and Australia's medical

and biotechnology ecosystem through their philanthropic and investment

activities, are proving transformational for the Australian life sciences

sector.

 

Minderoo's Collaborate Against Cancer initiative works with global partners to

overcome the greatest barriers to cancer prevention, diagnosis and treatment.

Through Minderoo, the Forrests are accelerating research and discovery of

breakthrough therapies to make world-class cancer care accessible to everyone,

no matter their address or background. In 2020, Minderoo mounted a pivotal

response to the COVID-19 pandemic to buffer Australia's diagnostic testing

capacity and personal protective equipment stockpiles in a time of critical

need.

 

Beyond their philanthropy, the Forrest family's Tarrarang Group has supported

Australian life science companies and recently launched Tenmile, a $250-million

venture capital fund dedicated to supporting innovators and companies to create

and nurture impactful health technology and biotech solutions. Tenmile seeks to

address unmet needs in healthcare and scale an Australian health science and

technology sector of global significance.

 

About AusBiotech

 

AusBiotech is Australia's biotechnology organisation, working on behalf of

members for more than 35 years to provide representation and services to

promote the global growth of Australian biotechnology. AusBiotech is a

well-connected network of over 3,000 members in the life sciences, including

therapeutics, medical technology (devices and diagnostics), food technology and

agricultural sectors.

 

source:AusBiotech

 

Image Attachments Links:

 

   Link: http://asianetnews.net/view-attachment?attach-id=432531

 

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中